SIF Documents on drugs for COVID-19

Eventi avversi dei vaccini anti-SARS-CoV-2 di Pfizer-BioNTech, Moderna, AstraZeneca e J&J

A cura di: Giuseppe Nocentini, Luigi Cari, Gianni Sava, Giorgio Racagni - 22 aprile 2021

Note sull’efficacia dei 4 vaccini anti-CoViD-19 attualmente in uso

A cura di: Giuseppe Nocentini, Luigi Cari, Gianni Sava, Giorgio Racagni

Eventi avversi dei vaccini anti-SARS-CoV-2 di Pfizer-Biontech, Moderna e AstraZeneca

A cura di Giuseppe Nocentini e Gianni Sava, Società Italiana di Farmacologia - 26 marzo 2021

Information sheet Intravenous tocilizumab for the treatment of patients with severe COVID-19 infection

Update March 16, 2021 - Edited by: Gianluca Trifirò, Valentina. Isgrò, Silvia Arena (University of Messina), Filippo Drago and Lucia Gozzo (University of Catania)

Chloroquine/hydroxychloroquine to prevent and treat COVID-19

Edited by: Gianluca Trifirò, Salvatore Crisafulli – University of Messina and Andrea Cignarella – University of Padova. October 16, 2020 update by Gianluca Trifirò, Salvatore Crisafulli, Andrea Cignarella

Information Data Sheet Remdesivir for intravenous use for the treatment of patients with COVID-19 (SARS-CoV-2) syndrome

Edited by: Antonio D’Avolio, Associate Professor of Pharmacology, University of Turin, and Valeria Avataneo, PhD, University of Turin.

DARUNAVIR/COBICISTAT

Edited by Annalisa Capuano, Società Italiana di Farmacologia, SIF Crisis Unit on SARS-CoV-2, Alessia Zinzi, University of Campania “Luigi Vanvitelli”

EMAPALUMAB

Edited by: Annalisa Capuano, SIF Crisis Unit on SARS-CoV-2, Carmen Ferrajolo and Mario Gaio, University of Campania “Luigi Vanvitelli”

ANAKINRA

Edited by Annalisa Capuano, Società Italiana di Farmacologia, SIF Crisis Unit on SARS-CoV-2, Carmen Ferrajolo, Gabriella di Mauro, University of Campania “Luigi Vanvitelli”

COVID-19 hazard in patients with rare diseases. What drugs to take with caution?

Edited by Sabata Pierno and Annamaria De Luca – SIF Crisis Unit on SARS-CoV-2 and University of Bari

SARILUMAB

Edited by: Annalisa Capuano, SIF Crisis Unit on SARS-CoV- 2, Carmen Ferrajolo and Federica Fraenza, University of Campania “Luigi Vanvitelli”

Safe use of sanitizers against SARS-CoV-2

Edited by Valerio Ciccone, Shirley Genah and Marina Ziche SIF Crisis Unit on SARS-CoV-2 and University of Siena

FAVIPIRAVIR

Edited by: Annalisa Capuano, SIF Crisis Unit on SARS-CoV-2, Carmen Ferrajolo, University of Campania “Luigi Vanvitelli”

Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections. A literature review

Edited by the Section of Clinical Pharmacology of the Italian Society of Pharmacology

Official statement of the Italian Society of Pharmacology on the use of ACE-inhibitors or angiotensin receptor blockers in COVID-19 infection

Edited by Prof. Gianluca Trifirò, by the Section of Clinical Pharmacology of the Italian Society of Pharmacology (SIF) and by the Cardiovascular and Metabolic Working Groups of SIF